The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children
Abstract
OBJECTIVE. Gastric acidity (GA) inhibitors, including histamine-2 receptor antagonists (H2 blockers) and proton pump inhibitors (PPIs), are the mainstay of gastroesophageal reflux disease (GERD) treatment. A prolonged GA inhibitor–induced hypochlorhydria has been suggested as a risk factor for severe gastrointestinal infections. In addition, a number of papers and a meta-analysis have shown an increased risk of pneumonia in H2-blocker–treated intensive care patients. More recently, an increased risk of community-acquired pneumonia associated with GA inhibitor treatment has been reported in a large cohort of adult patients. These findings are particularly relevant to pediatricians today because so many children receive some sort of GA-blocking agent to treat GERD. To test the hypothesis that GA suppression could be associated with an increased risk of acute gastroenteritis and pneumonia in children treated with GA inhibitors, we conducted a multicenter, prospective study. METHODS. The study was performed by expert pediatric gastroenterologists from 4 pediatric gastroenterology centers. Children (aged 4–36 months) consecutively referred for common GERD-related symptoms (for example, regurgitation and vomiting, feeding problems, effortless vomiting, choking), from December 2003 to March 2004, were considered eligible for the study. Exclusion criteria were a history of GA inhibitors therapy in the previous 4 months, Helicobacter pylori infection, diabetes, chronic lung or heart diseases, cystic fibrosis, immunodeficiency, food allergy, congenital motility gastrointestinal disorders, neuromuscular diseases, or malnutrition. Control subjects were recruited from healthy children visiting the centers for routine examinations. The diagnosis of GERD was confirmed in all patients by standard criteria. GA inhibitors (10 mg/kg ranitidine per day in 50 children or 1 mg/kg omeprazole per day in 50 children) were prescribed by the physicians for 2 months. All enrolled children were evaluated during a 4-month follow-up. The end point was the number of patients presenting with acute gastroenteritis or community-acquired pneumonia during a 4-month follow-up study period. RESULTS. We obtained data in 186 subjects: 95 healthy controls and 91 GA-inhibitor users (47 on ranitidine and 44 on omeprazole). The 2 groups were comparable for age, gender, weight, length, and incidence of acute gastroenteritis and pneumonia in the 4 months before enrollment. Rate of subjects presenting with acute gastroenteritis and community-acquired pneumonia was significantly increased in patients treated with GA inhibitors compared with healthy controls during the 4-month follow-up period. In the GA inhibitor-treated group, the rate of subjects presenting with acute gastroenteritis and community-acquired pneumonia was increased when comparing the 4 months before and after enrollment. No differences were observed between H2 blocker and PPI users in acute gastroenteritis and pneumonia incidence in the previous 4 months and during the follow-up period. On the contrary, in healthy controls, the incidence of acute gastroenteritis and pneumonia remained stable. CONCLUSIONS. This is the first prospective study performed in pediatric patients showing that the use of GA inhibitors was associated with an increased risk of acute gastroenteritis and community-acquired pneumonia in GERD-affected children. It could be interesting to underline that we observed an increased incidence of intestinal and respiratory infection in otherwise healthy children taking GA inhibitors for GERD treatment. On the contrary, the majority of the previous data showed that the patients most at risk for pneumonia were those with significant comorbid illnesses such as diabetes or immunodeficiency, and this points to the importance of GA suppression as a major risk factor for infections. In addition, this effect seems to be sustained even after the end of therapy. The results of our study are attributable to many factors, including direct inhibitory effect of GA inhibitors on leukocyte functions and qualitative and quantitative gastrointestinal microflora modification. Additional studies are necessary to investigate the mechanisms of the increased risk of infections in children treated with GA inhibitors, and prophylactic measures could be considered in preventing them.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut flora in health and disease
Guarner, F., & Malagelada, J.-R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12489-0 · Cited by 3,365
Risk of Community-Acquired Pneumonia and Use of Gastric Acid–Suppressive Drugs
Laheij, R. J. F. (2004) · JAMA · doi:10.1001/jama.292.16.1955 · Cited by 877
Dial, S. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1040876 · Cited by 577
Pediatric Gastrointestinal Disease
Walker, W. A. (2004) · Cited by 440
Bourlioux, P., Koletzko, B., Guarner, F., & Braesco, V. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/78.4.675 · Cited by 348
Thorens, J., Froehlich, F., Schwizer, W., Saraga, E., Bille, J., Gyr, K., Duroux, P., Nicolet, M., Pignatelli, B., Blum, A. L., et al. (1996) · Gut · doi:10.1136/gut.39.1.54 · Cited by 339
Treatment of early Parkinson's disease
Marsh, L., & Dawson, T. M. (2000) · BMJ · doi:10.1136/bmj.321.7252.1 · Cited by 337
Gastric Juice: A Barrier Against Infectious Diseases
Martinsen, T. C., Bergh, K., & Waldum, H. L. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto960202.x · Cited by 296
Prod'hom, G., Leuenberger, P., Koerfer, J., Blum, A., Chiolero, R., Schaller, M.-D., Perret, C., Spinnler, O., Blondel, J., Siegrist, H., et al. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-8-199404150-00005 · Cited by 264
Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study: Table 1
Neal, K. R., Scott, H. M., Slack, R. C. B., & Logan, R. F. A. (1996) · BMJ · doi:10.1136/bmj.312.7028.414 · Cited by 162
Simms, H. H., DeMaria, E., McDonald, L., Peterson, D., Robinson, A., & Burchard, K. W. (1991) · PubMed · Cited by 78
Role of Gastric Colonization in the Development of Pneumonia in Critically 111 Trauma Patients
Simms, H. H., DEMARIA, E., MCDONALD, L., PETERSON, D., ROBINSON, A., & BURCHARD, K. W. (1991) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/00005373-199104000-00013 · Cited by 76
Vannier, E. G., & Dinarello, C. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36975-2 · Cited by 73
O’Keefe, G. E., Gentilello, L. M., & Maier, R. V. (1998) · Annals of Surgery · doi:10.1097/00000658-199801000-00017 · Cited by 54
Coinfection with Giardia lamblia and Clostridium difficile after Use of Ranitidine
Khatami, S. S., Ravakhah, K., & Mukunda, B. N. (2004) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200402000-00007 · Cited by 20
Cited by
Rosen, R., Vandenplas, Y., Singendonk, M., Cabana, M., DiLorenzo, C., Gottrand, F., Gupta, S., Langendam, M., Staiano, A., Thapar, N., et al. (2018) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001889 · Cited by 1,557
The diagnosis and management of rhinitis: An updated practice parameter
WALLACE, D., DYKEWICZ, M., BERNSTEIN, D., BLESSINGMOORE, J., COX, L., KHAN, D., LANG, D., NICKLAS, R., OPPENHEIMER, J., & PORTNOY, J. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.06.003 · Cited by 1,096
Harris, M., Clark, J., Coote, N., Fletcher, P., Harnden, A., McKean, M., Thomson, A., & On behalf of the British Thoracic Society Standards of Care Committee (2011) · Thorax · doi:10.1136/thoraxjnl-2011-200598 · Cited by 1,095
Consensus Statement for Standard of Care in Spinal Muscular Atrophy
Wang, C. H., Finkel, R. S., Bertini, E. S., Schroth, M., Simonds, A., Wong, B., Aloysius, A., Morrison, L., Main, M., Crawford, T. O., et al. (2007) · Journal of Child Neurology · doi:10.1177/0883073807305788 · Cited by 961
Vandenplas, Y., Rudolph, C. D., Committee Members:, Di Lorenzo, C., Hassall, E., Liptak, G., Mazur, L., Sondheimer, J., Staiano, A., Thomson, M., et al. (2009) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e3181b7f563 · Cited by 742
Metadata
- Authors
- Canani, R. B., Cirillo, P., Roggero, P., Romano, C., Malamisura, B., Terrin, G., Passariello, A., Manguso, F., Morelli, L., Guarino, A., & for the Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, H. A. N. (.
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2006-05-01
- Volume
- 117
- Issue
- 5
- Pages
- e817-e820
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2043669396
- Cited by
- 398
- References
- 16
- FWCI
- 16.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.